title: The clinical benefit of in-hospital observation in 'low-risk' pneumonia patients after conversion from parenteral to oral antimicrobial therapy.
abstract: OBJECTIVE
  To assess the benefit of in-hospital observation in "low-risk" patients with community-acquired pneumonia.
  
  
  METHODS
  Retrospective review of data from a prospective study.
  
  
  METHODS
  Teaching community hospital.
  
  
  METHODS
  We studied 717 consecutive, adult patients admitted to the hospital for pneumonia.
  
  
  RESULTS
  One hundred forty-five patients were classified at low-risk for complications using previously studied criteria; 144 (99%) charts were available for review. Two patients had "obvious reasons for continued hospitalization" on the day of antibiotic conversion and were excluded. One hundred two patients were observed, and 40 were not observed in-hospital after switch to oral antibiotics. No patient from either group required medical intervention within 24 h after hospital discharge. Five "observed" patients (5%, 95% confidence interval [CI], 2 to 11%) returned to the emergency department, three (3%; 95% CI, 0 to 9%) with respiratory complaints. Two (2%; 95% CI, 0 to 7%) "observed" patients were admitted to the hospital with recurrent pneumonia. One (3%; 95% CI, 0 to 13%) "not observed" patient returned to the emergency department with a nonrespiratory complaint and was not admitted. No patient from either group died within 30-day clinical follow-up. The length of stay for the "observed" and "not observed" groups was 98+/-33 h and 83+/-49 h, respectively. The difference in length of stay was 15 h (95% CI, 3 to 27).
  
  
  CONCLUSIONS
  In-hospital observation for low-risk patients admitted with community-acquired pneumonia after switch from parenteral to oral antibiotics is of limited benefit, and elimination of this practice could potentially reduce length of stay by almost 1 day per patient. This could translate into a cost savings of $57,200 for the 22-month study period. These results require prospective validation in a larger study.
authors.affiliation: Department of Health Services Research, Cedars-Sinai Health System and UCLA School of Medicine, Los Angeles, USA.
authors.forename: D C
authors.initials: DC
authors.lastname: Rhew
authors.forename: D
authors.initials: D
authors.lastname: Hackner
authors.forename: L
authors.initials: L
authors.lastname: Henderson
authors.forename: A G
authors.initials: AG
authors.lastname: Ellrodt
authors.forename: S R
authors.initials: SR
authors.lastname: Weingarten
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy* / Q000191:economics; D003365:Costs and Cost Analysis; D005260:Female; D005500:Follow-Up Studies; D006302:Health Services Research; D006760:Hospitalization / Q000191:economics; D006801:Humans; D007263:Infusions, Parenteral; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000188:drug therapy* / Q000191:economics; D011446:Prospective Studies; D012008:Recurrence; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents